S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

$16.79
+0.88 (+5.53%)
(As of 03/1/2024 ET)
Today's Range
$16.26
$17.19
50-Day Range
$7.23
$17.47
52-Week Range
$3.21
$18.33
Volume
11.01 million shs
Average Volume
15.12 million shs
Market Capitalization
$4.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.55

Iovance Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
46.2% Upside
$24.55 Price Target
Short Interest
Bearish
20.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.43mentions of Iovance Biotherapeutics in the last 14 days
Based on 41 Articles This Week
Insider Trading
Acquiring Shares
$2.29 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.40) to ($0.64) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.76 out of 5 stars

Medical Sector

58th out of 950 stocks

Biological Products, Except Diagnostic Industry

8th out of 152 stocks


IOVA stock logo

About Iovance Biotherapeutics Stock (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Stock Price History

IOVA Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Iovance Biotherapeutics: Q4 Earnings Insights
Iovance Biotherapeutics's Earnings: A Preview
Stock Offerings Prompt Big Insider Buying
3 Stocks Flashing Recent Insider Buying Signals
Iovance Biotherapeutics (IOVA) to Release Earnings on Wednesday
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/03/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
503
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$24.55
High Stock Price Target
$34.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+46.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-395,890,000.00
Pretax Margin
-37,638.01%

Debt

Sales & Book Value

Annual Sales
$1.19 million
Book Value
$2.09 per share

Miscellaneous

Free Float
229,303,000
Market Cap
$4.69 billion
Optionable
Optionable
Beta
0.62

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 50)
    J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary
    Comp: $1.39M
  • Mr. Jean-Marc Bellemin M.B.A. (Age 51)
    CFO, Principal Accounting Officer & Treasurer
    Comp: $932.2k
  • Dr. Igor P. Bilinsky (Age 51)
    Chief Operating Officer
    Comp: $932.2k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 57)
    Chief Medical Officer
    Comp: $1.06M
  • Ms. Sara Pellegrino
    Vice President of Investor Relations & Public Relations
  • Ms. Tracy Winton
    Senior Vice President of Human Resources
  • Mr. Howard B. Johnson M.B.A. (Age 64)
    Chief Business Officer
  • Mr. James Ziegler M.B.A.
    Executive Vice President of Commercial
  • Dr. Raj K. Puri M.D.
    Ph.D., Executive VP of Regulatory Strategy & Translational Medicine
  • Mr. Brian Shew M.B.A.
    Senior VP & Head of Digital and Information Technology














IOVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price target for 2024?

10 analysts have issued 12-month price objectives for Iovance Biotherapeutics' shares. Their IOVA share price targets range from $17.00 to $34.00. On average, they predict the company's share price to reach $24.55 in the next twelve months. This suggests a possible upside of 46.2% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2024?

Iovance Biotherapeutics' stock was trading at $8.13 at the beginning of 2024. Since then, IOVA stock has increased by 106.5% and is now trading at $16.79.
View the best growth stocks for 2024 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.01. The biotechnology company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $1.44 million. During the same period in the prior year, the business posted ($0.64) EPS.

What ETFs hold Iovance Biotherapeutics' stock?
What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.91%), Perceptive Advisors LLC (4.68%), Artisan Partners Limited Partnership (1.89%), Balyasny Asset Management L.P. (1.53%), Goldman Sachs Group Inc. (1.44%) and Goldman Sachs Group Inc. (1.44%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IOVA) was last updated on 3/3/2024 by MarketBeat.com Staff